ClinicalTrials.gg
RecruitingNCT06874556Updated Apr 16, 2026

A Study of Paramedic HF Management

An observational study in Heart Failure, sponsored by Mayo Clinic. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-04-16.

Sponsored by Mayo Clinic · Observational

How we know

From the registry’s dates

  • Started Jun 2025; still recruiting 1 year 4 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
75
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 69 studies in Heart Failure by Mayo Clinic — 16 open to participants now, 17 under way, none of them phase 3. Heart Failure · Mayo Clinic.

Planned enrollment
8th of 18
75 · median 63
Started
2025
with 5 others
Observational
21 of 69
6 open now
Primary completion
2026-12
later than 1 of 16 live
Registered
62nd of 69
by date

Among the 69 studies in Heart Failure by Mayo Clinic, this one is the 8th largest by planned enrollment of the 18 observational ones that give a count, is one of 6 that started in 2025, is one of 21 observational ones, reaches primary completion later than 1 of the 16 other live ones, and was the 62nd registered.

Heart Failure

6,340 studies on the registry are indexed under Heart Failure; 1,397 are open to participants now.

Browse Heart Failure studies →

Open to participants now

16 of the 69 studies in Heart Failure by Mayo Clinic are open now, in 1 country. Recruiting first, the newest first:

10 more — sign in →

By country, each count listing its studies:

All 16 open studies →

Where they have run

Who these studies take

Of the 968 Heart Failure studies recruiting now, 691 (71%) set no upper age limit and 90 (9%) stop at 75 or younger; 64 take children under 18; 97 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 69 studies in Heart Failure by Mayo Clinic, or all of them as a file.
02

Study summary

The purpose of this research is to see if having community paramedic (CP) visit patients at home to manage their heart failure help them stay out of the hospital and improve their overall health compared to standard care. The investigators want to find out if their approach is better for patients in terms of their quality of life, hospital stays, emergency visits, and cost. The investigators are also looking to see how happy patients and doctors are with this method and if it's a practical and sustainable option for the future.

03

Conditions studied

  • Heart Failure

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

Patients will be identified by the inpatient cardiology services along with outpatient cardiology and/or primary care offices.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

One of the following criteria:

  1. Adults admitted to the hospital with decompensated HF eligible for early discharge with CP support and monitoring.
  2. Acutely decompensated HF patients at home or being evaluated in the ambulatory clinic who require large volume diuresis but do not require hospital-level monitoring.
  3. Stage D advanced HF patients who require frequent (>weekly) diuretic adjustments (either inpatient or outpatients).

Exclusion criteria

Exclusion Criteria:

  1. Hospital-level monitoring or care is clinically indicated.
  2. Failed safety assessment, active substance abuse, or behavioral health diagnosis which could impact participation.
  3. Enrolled in hospice.
  4. Patient is a resident in a skilled nursing facility.
  5. Patient does not have a primary care physician or cardiologist at Mayo Clinic.
  6. Patient participants with communication barriers due to medical illness or cognitive impairment.
  7. Pregnant
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
75 participants (estimated)
Patient registry
No

Groups and cohorts

  • Community Paramedic Heart Failure Management (CP-HF) program

    Behavioral: CP-HF Management

  • Standard of Care (SOC)

Interventions

  • BehavioralCP-HF Management

    Community Paramedics will visit patients up to twice daily. Visits will include patient care discussion with Heart Failure APP, IV placement, lab phlebotomy, heart failure education, and IV medication administration. Community Paramedics will administer up to 120 mg IV furosemide twice daily.

06

What researchers measure

Primary outcomes

  1. Number of Days without Hospitalization

    Number of Days without Hospitalization will be measured by the number of days a patient is not admitted to the hospital.

    Time frame: From date of randomization until the date of first documented progression or date of death from any cause, whichever comes first, assessed up to 12 months

  2. Number of Days in the Hospital

    Number of Days in the Hospital will be determined by a patient's length of hospital stay.

    Time frame: From date of randomization until the date of first documented progression or date of death from any cause, whichever comes first, assessed up to 12 months

  3. Number of Emergency Department (ED) Visits

    Number of Emergency Department (ED) Visits will be determined by the number of ED visits per patient

    Time frame: From date of randomization until the date of first documented progression or date of death from any cause, whichever comes first, assessed up to 12 months

  4. Number of Hospitalizations

    Number of Hospitalizations will be determined by the number of patients that are hospitalized.

    Time frame: From date of randomization until the date of first documented progression or date of death from any cause, whichever comes first, assessed up to 12 months

  5. Minnesota Living with Heart Failure Questionnaire (MLHFQ)

    Minnesota Living with Heart Failure Questionnaire (MLHFQ) is a 21-question quality of life questionnaire. The scores can range from 0-105, with a higher score reflecting a worse quality of life

    Time frame: Baseline, 31 Days

  6. Number of patients to comply with the guideline-directed medical therapy (GDMT)

    Number of patients to comply with the guideline-directed medical therapy (GDMT) will be measured through medical record reviews to determine changes in adherence rates to prescribed HF medications and therapies.

    Time frame: From date of randomization until the date of first documented progression or date of death from any cause, whichever comes first, assessed up to 12 months

Secondary outcomes

  1. Patient Satisfaction

    Measured through a structured patient satisfaction survey developed for the CP-HF program. The survey assesses various aspects of patient experience, including communication, responsiveness, medication management, and overall satisfaction. Responses are rated on a 5-point Likert scale (1 = Strongly Disagree, 5 = Strongly Agree), with higher scores indicating greater satisfaction. Additional questions evaluate care coordination, interpreter service utilization, perceived safety, and willingness to recommend the program.

    Time frame: up to 1 year

  2. Clinician Satisfaction

    Measured through the Clinician \& Stakeholder Satisfaction Survey, which assesses clinician experiences and perceptions of the CP-HF program's effectiveness. The survey includes questions on program structure, implementation, sustainability, and collaboration. Responses are rated on a 5-point Likert scale, with higher scores indicating greater satisfaction.

    Time frame: up to 1 year

  3. Stakeholder-Perceived Sustainability

    Stakeholder-Perceived Sustainability will be measured through interviews and surveys of key stakeholders to gauge their views on the sustainability and scalability of the CP-HF program.

    Time frame: up to 1 year

  4. Cost-effectiveness of Community Paramedic Program

    Cost-effectiveness will be determined by comparing the measured cost of the community Paramedic Program against the Standard of Care (SOC)

    Time frame: up to 1 year

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2025 (actual). Primary completion is estimated for Dec 2026, 18 months after the start.

Of 799 non-industry observational studies under Heart Failure, half reached primary completion within 45 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 100. This study's planned 18 months is below that.

Counting every sponsor, half of 982 studies reached it within 41 months; a quarter within 23 and three quarters within 89.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 3, 2025
First posted
Mar 13, 2025
StartActual
Jun 24, 2025
Primary completionEst.
Dec 2026
CompletionEst.
Jan 2027
Last update
Apr 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 16, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06874556
Lead sponsor
Mayo Clinic
Responsible party
Sara B. Severson (Principal Investigator, Mayo Clinic) — Principal investigator
First posted
Mar 13, 2025
Start date
Jun 24, 2025
Primary completion
Dec 2026 (estimated)
Completion
Jan 2027 (estimated)
Last update
Apr 16, 2026

Study contacts

Sara Biorn
Contact
Biorn.Sara@mayo.edu
507-266-2328
Sara Severson, APRN, C.N.P.
principal investigator · Mayo Clinic

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion